. "Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function. [PubChem]"@en . . . "Proteus mirabilis"@en . "(2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"@en . . . . "Enteric bacteria and other eubacteria"@en . . "N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid"@en . . . . . . "4697-36-3"@en . "approved"@en . . "Take on an empty stomach."@en . "Carbenicillin"@en . . . " "@en . . "Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%."@en . "Gram-negative Bacteria"@en . "Free carbenicillin is the predominant pharmacologically active fraction of the salt. Carbenicillin exerts its antibacterial activity by interference with final cell wall synthesis of susceptible bacteria. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that carbenicillin interferes with an autolysin inhibitor."@en . . . . . . "Carbenicilina"@en . . "1 hour"@en . . "Brain, E.G. and Nayler, J.H.C.; US. Patents 3,282,926; November 1,1966 and 3,492,291; January 27,1970; both assigned to Beecham Group Limited, England."@en . . . . . . "alpha-Phenyl(carboxymethylpenicillin)"@en . . . "Carbenicillin"@en . . . . . "Carbenicilline"@en . "30 to 60%"@en . . . . . . . . "CBPC"@en . "alpha-Carboxybenzylpencillin"@en . "Carbenicillinum"@en . "Escherichia coli"@en . "For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria."@en . . . . . "Carboxybenzylpenicillin"@en . "Carbenicillin blood levels achievable are very low, and toxic reactions as a function of overdosage should not occur systematically. The oral LD₅₀ in mice is 3,600 mg/kg, in rats 2,000 mg/kg, and in dogs is in excess of 500 mg/kg. The lethal human dose is not known. Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting."@en . . "Pseudomonas aeruginosa"@en . .